Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
23andme
anne wojcicki
astellas pharma
atlas venture
audentes therapeutics
avidity biosciences
biotech
bluebird bio
boston
boston blog main
boston top stories
business
clinical trials
dna
duchenne muscular dystrophy
dyne therapeutics
facioscapulohumeral muscular dystrophy
gear
gene therapy
genetic testing
genetics
jobs
joshua brumm
kaleido biosciences
layoffs
life sciences
medicine
muscular dystrophy
myotonic dystrophy type 1
national blog main
national top stories
new york blog main
rare disease drugs
romesh subramanian
san diego blog main
san francisco blog main
susanna high
vertex pharmaceuticals
What
expected
2
×
genetic
2
×
acknowledging
ago
amid
andme
biotechs
considering
data
demand
diseases
dna
drug
dyne
early
experimental
eyes
having
hot
humans
ipo
ipos
isn't
lays
long
market
medicines
muscle
rare
reach
shrinking
testing
tests
therapeutics
worked
workers
Language
unset
2
×
Current search:
expected
×
genetic
×
unset
×
@xconomy.com
3 years ago
Dyne Eyes IPO for R&D of Genetic Medicines for Rare Muscle Diseases
@engadget.com
4 years ago
23andMe lays off 100 workers amid shrinking demand for DNA tests
